Quick Answer
Oaktree Acquisition Corp. III Life Sciences reported Stockholders Equity of -$6.77 million for fiscal year 2025.
Oaktree Acquisition Corp. III Life Sciences Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$6.77M | -11.5% |
| 2024 | -$6.07M | — |
| 2024 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.76M | -29190.6% | -3.4% |
| June 30, 2025 | -$6.54M | -26256.3% | -0.3% |
| March 31, 2025 | -$6.52M | — | -7.3% |
| December 31, 2024 | -$6.07M | — | -26202.1% |
| September 30, 2024 | -$23.1K | — | -192.4% |
| June 30, 2024 | $25.0K | — | — |
- Oaktree Acquisition Corp. III Life Sciences showed a decrease of -11.5% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Oaktree Acquisition Corp. III Life Sciences’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: